Analysts Set Equillium, Inc. (NASDAQ:EQ) Target Price at $6.00

Shares of Equillium, Inc. (NASDAQ:EQ) have been given an average recommendation of “Hold” by the five research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $6.00.

A number of equities analysts have recently commented on EQ shares. Roth Mkm assumed coverage on Equillium in a report on Friday. They set a “buy” rating and a $12.00 price target for the company. Stifel Nicolaus initiated coverage on Equillium in a research report on Wednesday, February 25th. They issued a “buy” rating and a $5.00 target price on the stock. Wall Street Zen raised Equillium from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Equillium in a report on Monday, December 29th. Finally, Zacks Research upgraded shares of Equillium to a “hold” rating in a research note on Thursday, February 26th.

Insider Buying and Selling

In related news, COO Christine Zedelmayer sold 185,937 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $1.76, for a total value of $327,249.12. Following the completion of the transaction, the chief operating officer owned 191,444 shares of the company’s stock, valued at $336,941.44. This represents a 49.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders have sold 473,689 shares of company stock valued at $848,115. 30.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC bought a new position in shares of Equillium in the 4th quarter valued at $9,057,000. ADAR1 Capital Management LLC bought a new stake in Equillium during the 3rd quarter worth $7,951,000. Woodline Partners LP bought a new stake in Equillium during the 3rd quarter worth $5,018,000. Aberdeen Group plc increased its holdings in Equillium by 523.6% in the 4th quarter. Aberdeen Group plc now owns 2,366,688 shares of the company’s stock worth $3,668,000 after purchasing an additional 1,987,162 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Equillium by 59.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company’s stock worth $1,879,000 after purchasing an additional 489,855 shares in the last quarter. 27.05% of the stock is currently owned by institutional investors and hedge funds.

Equillium Price Performance

NASDAQ EQ opened at $2.47 on Friday. The business has a fifty day moving average price of $1.54 and a two-hundred day moving average price of $1.41. The stock has a market capitalization of $150.40 million, a PE ratio of -3.98 and a beta of 1.80. Equillium has a fifty-two week low of $0.27 and a fifty-two week high of $2.63.

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.